Inhibitors & Agonists

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DCAPI1491	Celecoxib Featured	Celecoxib is a selective Cox-2 inhibitor (IC50 of 40 nM). Celecoxib shows low sensitivity against Cox-1 (IC50 of 15 μM). Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 (IC50of 32.86 μM) and CNE1-LM
DC7569	Z-LEHD-FMK	Cell permeable fluoromethyl ketone (FMK)-derivatized peptides act as effective irreversible Caspase inhibitors with no cytotoxic effects and, therefore, are useful tools for studying Caspase activity.
DC7568	Z-DEVD-FMK Featured	Cell-permeable, irreversible inhibitor of caspase-3/CPP32; inhibits tumor cell apoptosis. Neuroprotective in rat hippocampus following seizures in vivo.
DC9923	CeMMEC1 Featured	CeMMEC1 is a novel potent inhibitor of the second bromodomain of TAF1, binding neither the first nor the second bromodomain of BRD4.
DC23359	CeMMEC2	CeMMEC2 is a novel potent BRD4 inhibitor with IC50 of 0.9 uM, binds to both bromodomains of BRD4, comparably to (S)-JQ1..
DC10357	Cenerimod	Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM.
DC10316	Cenicriviroc Featured	Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.
DC21554	AS 703569	Cenisertib (AS 703569;R763) is a novel potent, orally available inhibitor of Aurora kinases, exhibits signifficant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo (A549 EC50=9 nM).
DC12318	Centanafadine hydrochloride (EB-1020 (hydrochloride))	Centanafadine (hydrochloride) is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.
DC12319	Centanafadine (EB-1020)	Centanafadine is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.
DC10011	Centrinone-B	Centrinone-B is a high affinity and selective PLK4 inhibitor (Ki = 0.59 nM).
DC22796	CEP-1347	CEP-1347 (KT-7515) is a potent and selective MLK inhibitor that completely rescues motoneurons and inhibits JNK1 activation with IC50 of 20 nM.
DC8138	CEP-28122 Featured	CEP-28122 is a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
DC8777	CEP-32496 hydrochloride	CEP-32496 Hcl is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.
DC8196	CEP-32496 Featured	CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.
DC7099	CEP33779 Featured	CEP33779(< 3 μM) inhibits phosphorylation of downstream target signal transducer and activator of transcription 5(pSTAT5) of JAK2 in a concentration dependent manner in HEL92 cells.
DC8009	CEP-37440 Featured	CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
DC10337	CEP-40783 Featured	CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
DC23856	CEP-7055	CEP-7055 is a potent, orally active, pan inhibitor of VEGFR, CEP-7055 is the dimethylglycine ester prodrug of CEP-5214, which inhibits human VEGFR2/KDR kinase, VEGFR1/FLT-1 kinase, and VEGFR3/FLT-4 kinase with IC50 of 18 nM, 12 nM, and 17 nM.
DC7347	Cephalosporin C Na salt Featured	Cephalosporin C Na salt is used to study the effect of transpeptidase expression, binding, and inhibition on bacterial cell wall mucopeptide synthesis.
DC7346	Cephalosporin C zinc salt Featured	Cephalosporin C zinc salt is used to study the effect of transpeptidase expression, binding, and inhibition on bacterial cell wall mucopeptide synthesis.
DC9649	Cephalotaxlen Featured	Cephalotaxine is an antiviral as well as antitumor agent.
DC10226	Cefradine	Cephradine is a semi-synthetic cephalosporin antibiotic.
DC9765	CERC-501(LY-2456302,Aticaprant) Featured	CERC-501(LY-2456302) is a potent, selective antagonist of the kappa opioid receptor (KOR) (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ-opioid receptor (MOR) and δ-opioid receptor (DOR), respectively.
DC7814	Cerdulatinib(PRT-062070; PRT2070) Featured	Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor.
DC9154	Cetirizine 2HCl	Cetirizine 2Hcl, a second-generation antihistamine, is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, hay fever, angioedema, and urticaria.
DC9500	Cevimeline (hydrochloride hemihydrate) Featured	Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.
DC7899	Cevipabulin(TTI 237)	Cevipabulin, also known as TTI-237, an antimicrotubule agent, is a small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity.
DC10440	Namodenoson (CF-102) Featured	CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. target: A3 adenosine receptor agonist;
DC22052	CFI02	CFI02 (CFI-02) is a specific inhibitor of human cytomegalovirus (HCMV) glycoprotein B-mediated fusion with IC50 of 40 nM against laboratory adapted HCMV strain AD169.

<Prev1...150 151 152 153 154...1254 Next>

Inhibitors & Agonists

Customized Consultation X

Your information is safe with us. * Required Fields.